Novartis | NVS - Ebitda


Novartis reported $5.41B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bausch Health Companies USD 1.08B 238M Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Canopy Growth CAD -137M 134.13M Mar/2026
Corcept Therapeutics USD -49M 53.2M Mar/2026
Drreddys Laboratories INR 8.63B 12.96B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Sanofi EUR 2.72B 2.94B Mar/2026
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
Zoetis USD 939M 101M Dec/2025